Subchronic Phencyclidine Administration Increases Mesolimbic Dopaminergic System Responsivity and Augments Stress- and Psychostimulant-Induced Hyperlocomotion

[1]  R. Roth,et al.  Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. , 1997, Science.

[2]  R. Roth,et al.  Subchronic Phencyclidine Administration Reduces Mesoprefrontal Dopamine Utilization and Impairs Prefrontal Cortical-Dependent Cognition in the Rat , 1997, Neuropsychopharmacology.

[3]  Daniel R. Weinberger,et al.  Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood , 1997, Psychopharmacology.

[4]  R. Roth,et al.  Phencyclidine Increases Forebrain Monoamine Metabolism in Rats and Monkeys: Modulation by the Isomers of HA966 , 1997, The Journal of Neuroscience.

[5]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[6]  Edward D. Levin,et al.  Cognitive Effects of Neonatal Hippocampal Lesions in a Rat Model of Schizophrenia , 1996, Neuropsychopharmacology.

[7]  D. Weinberger,et al.  Prefrontal function in schizophrenia: confounds and controversies. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[8]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Meador-Woodruff,et al.  Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems , 1996, Brain Research.

[10]  R. Steinpreis.  The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis , 1996, Behavioural Brain Research.

[11]  F. Sams-Dodd.  Phencyclidine‐induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia , 1996, Behavioural pharmacology.

[12]  T. Svensson,et al.  Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat , 1995, Behavioural Brain Research.

[13]  Karl J. Friston,et al.  Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia , 1995, Nature.

[14]  A. Gratton,et al.  Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function. , 1995, European journal of pharmacology.

[15]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[16]  M. Egan,et al.  Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol , 1995, Synapse.

[17]  G. Ellison.  The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias , 1995, Brain Research Reviews.

[18]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[19]  H. Meltzer,et al.  Effects of clozapine on cognitive function in schizophrenia. , 1994, The Journal of clinical psychiatry.

[20]  D. Weinberger,et al.  Subchronic Treatment with Haloperidol and Clozapine in Rats with Neonatal Excitotoxic Hippocampal Damage , 1994, Neuropsychopharmacology.

[21]  A C Roberts,et al.  6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  J. Salamone,et al.  The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat , 1994, Pharmacology Biochemistry and Behavior.

[23]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[24]  Larry J. Seidman,et al.  Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia , 1994, Biological Psychiatry.

[25]  B. Lipska,et al.  Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. , 1993, Brain research. Developmental brain research.

[26]  G. Martin,et al.  The early development of major projections from caudal levels of the spinal cord to the brainstem and cerebellum in the gray short-tailed Brazilian opossum, Monodelphis domestica. , 1993, Brain research. Developmental brain research.

[27]  D. Weinberger,et al.  Postpubertal Emergence of Hyperresponsiveness to Stress and to Amphetamine after Neonatal Excitotoxic Hippocampal Damage: A Potential Animal Model of Schizophrenia , 1993, Neuropsychopharmacology.

[28]  Sohee Park,et al.  Schizophrenics show spatial working memory deficits. , 1992, Archives of general psychiatry.

[29]  N C Andreasen,et al.  Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. , 1992, Archives of general psychiatry.

[30]  M. LeMay,et al.  Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. , 1992, The New England journal of medicine.

[31]  R. Roth,et al.  Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in mesolimbic and nigrostriatal dopamine systems , 1992, Neuroscience.

[32]  R. Murray,et al.  A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia , 1992, Schizophrenia Research.

[33]  Karl J. Friston,et al.  Patterns of Cerebral Blood Flow in Schizophrenia , 1992, British Journal of Psychiatry.

[34]  A. Grace.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[35]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[36]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[37]  J. Warter,et al.  Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat , 1991, Neuroscience Letters.

[38]  Douglas W. Jones,et al.  The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[39]  M. Buchsbaum,et al.  Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. , 1991, Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology.

[40]  Ariel Y. Deutch,et al.  Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress , 1990, Brain Research.

[41]  E. Kotlyarov,et al.  Single photon emission computed tomography in phencyclidine and related drug abuse. , 1990, The American journal of psychiatry.

[42]  R. Gur,et al.  Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: Relationship to symptom specificity , 1989, Psychiatry Research.

[43]  D. Weinberger,et al.  Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. , 1988, Archives of general psychiatry.

[44]  R. Roth,et al.  Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. , 1987, European journal of pharmacology.

[45]  D. Weinberger,et al.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.

[46]  H. Meltzer,et al.  Phencyclidine as an indirect dopamine agonist [proceedings]. , 1980, Psychopharmacology bulletin.

[47]  H. E. Rosvold,et al.  Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. , 1979, Science.

[48]  T. Itil,et al.  Effect of Phencyclidine in Chronic Schizophrenics * , 1967, Canadian Psychiatric Association journal.

[49]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[50]  E. Fey.  The performance of young schizophrenics and young normals on the Wisconsin Card Sorting Test. , 1951, Journal of consulting psychology.

[51]  A. Deutch.  The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. , 1992, Journal of neural transmission. Supplementum.

[52]  T. Newell,et al.  Recovery of neuropsychological functions during reduction in use of phencyclidine. , 1991, Journal of clinical psychology.

[53]  R. Roth,et al.  The determinants of stress-induced activation of the prefrontal cortical dopamine system. , 1990, Progress in brain research.

[54]  T. Robbins,et al.  The case of frontostriatal dysfunction in schizophrenia. , 1990, Schizophrenia bulletin.

[55]  D. Weinberger,et al.  The effect of apomorphine on regional cerebral blood flow in schizophrenia. , 1989, The Journal of neuropsychiatry and clinical neurosciences.

[56]  T. Goldberg,et al.  Probing prefrontal function in schizophrenia with neuropsychological paradigms. , 1988, Schizophrenia bulletin.

[57]  G. Pearlson.  Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. , 1981, The Johns Hopkins medical journal.

[58]  B. Angrist,et al.  Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. , 1977, Advances in biochemical psychopharmacology.